Medicamen Biotech Ltd banner
M

Medicamen Biotech Ltd
NSE:MEDICAMEQ

Watchlist Manager
Medicamen Biotech Ltd
NSE:MEDICAMEQ
Watchlist
Price: 268.41 INR 2.65% Market Closed
Market Cap: ₹3.6B

Medicamen Biotech Ltd
Investor Relations

Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is engaged in manufacturing pharmaceutical formulations products. The firm manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The firm is primarily focused on oncology therapeutics. The firm is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. The firm's oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, Nilotinib HCI, Oxaliplatin, Pazopanib, Pomalidomide and Tegafur. The firm has two manufacturing plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The firm's wholly owned subsidiary is OPAL Pharmaceuticals Pty Ltd.

Show more
Loading
MEDICAMEQ
BSE Sensex 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Rajesh Madan B. Pharma
Chief Executive Officer
No Bio Available
Ms. Parul Choudhary
Compliance Officer & Company Secretary
No Bio Available
Dr. Aneek Gupta
Head of Operations
No Bio Available

Contacts

Address
DELHI
New Delhi
1506, Chiranjiv Tower, 43, Nehru Place
Contacts
+911147589500
www.medicamen.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett